AMPE - Ampio Pharma on go with inhaled Ampion study in COVID-19

Ampio Pharmaceuticals (AMPE) soars 28% premarket after receiving an an Investigational New Drug ((IND)) from the FDA, allowing the Company to proceed with clinical trials for the use of Ampion as an inhalation therapy for respiratory distress due to COVID-19 infection. Phase I trial of inhaled Ampion will enroll 40 patients, and assess the safety and efficacy of inhaled Ampion added to the standard of care ((SOC)) for COVID-19 patients hospitalized for respiratory distress.Ampion will be delivered by a hand-held nebulizer for inhalation by patients with less severe cases of respiratory illness and through mechanical ventilators to those patients who have progressed to severe respiratory distress syndrome ((ARDS)).

For further details see:

Ampio Pharma on go with inhaled Ampion study in COVID-19